Abstract
Bullous pemphigoid is the most common autoimmune blistering skin disease. It typically affects elderly patients and is characterized by subepidermal bullae and in vivo deposition of autoantibodies and complement components and significant polymorphonuclear cell infiltrates along the epidermal basement membrane zone. Despite of its relatively benign course, an effective treatment should promptly be initiated to control and prevent the appearance of new blisters in a population of patients that is already commonly debilitated by concomitant chronic diseases. In this article we present our practical, yet comprehensive approach to the management of patients with bullous pemphigoid.
| Original language | English |
|---|---|
| Pages (from-to) | 369-373 |
| Number of pages | 5 |
| Journal | Dermatologic Therapy |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2002 |
| Externally published | Yes |
Keywords
- Bullous pemphigoid
- Cyclophosphamide
- Dapsone
- Mycophenolate mofetil
- Prednisone
